Novel biomarkers rapidly differentiate neurological disorders

Researchers in Switzerland have shown that biomarkers in cerebrospinal fluid (CSF) can help rapidly differentiate multiple sclerosis (MS) from other neurological disorders in the acute phase.

According to Dr David Leppert of the University of Basel, Switzerland, it is often difficult to differentiate among the acute phases of neuromyelitis optica spectrum disorders (NMOSD), anti-myelin oligodendrocyte glycoprotein (MOG) antibody associated disease (MOGAD), and relapsing/remitting MS (RRMS).